Is there human evidence for Retatrutide?

5 of the 5 studies indexed for Retatrutide observed people. The rest are preclinical. No regulator has approved retatrutide for any indication in any jurisdiction. It remains investigational.

What is not established about Retatrutide?

No regulator has approved retatrutide for any indication in any jurisdiction. It remains investigational. No independent replication outside the developer's own programme appears in the indexed literature. No long-term safety profile is established. Nothing in the trial literature concerns research-grade material sold outside the development programme.

Evidence digest

What the research on retatrutide actually shows

Retatrutide is investigational. The published trials were conducted by the compound's developer, no regulator has approved it for any indication anywhere, and there is no independent replication outside the development programme in the indexed literature. It is nonetheless listed by vendors in this index, which makes the gap between what is published and what is sold unusually wide for this compound.

Updated 22 Jul 2026 · 5 studies indexed · 5 human · compound record

Studies indexed: 5
Human evidence: 5
Preclinical only: 0

What is and is not established

What the literature supports

Developer-run human trials of the triple receptor agonist have been published.
The compound is listed by several vendors in this index as research-grade powder.

What is NOT established

No regulator has approved retatrutide for any indication in any jurisdiction. It remains investigational.
No independent replication outside the developer's own programme appears in the indexed literature.
No long-term safety profile is established.
Nothing in the trial literature concerns research-grade material sold outside the development programme.

Studies indexed

2 human — controlled trial · 2 systematic review · 1 meta-analysis

Each row links to that study's permalink, where every digest citing it is listed. Findings are reported as the paper reported them — an animal result is not restated as a human one.
Study	Evidence type	Model	n	What it reported	Source
Developer-run trials of retatrutidePubMed listing	Human — controlled trial	Not recorded	—	Placeholder seed record. Published trials of this investigational triple agonist were conducted by the compound's developer. The compound remains investigational and is not approved by any regulator; no independent replication outside the development programme is listed.	Listing
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialThe New England journal of medicine · 2023	Human — controlled trial	Not recorded	—	Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or…	PMID 37366315
Emerging pharmacotherapies for obesity: A systematic reviewPharmacological reviews · 2025	Systematic review	Not recorded	—	The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo…	PMID 39952695
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled TrialsAnnals of internal medicine · 2025	Systematic review	Not recorded	—	Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes. To assess the efficacy and safety of GLP-1 RAs and co-agonists for the treatment of obesity among adults without diabetes. MEDLINE, Embase, and Cochrane CENTRAL from inception to 4 October 2024. Placebo-controlled RCTs in otherwise healthy participants wit…	PMID 39761578
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trialsMetabolism: clinical and experimental · 2024	Meta-analysis	Not recorded	—	This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis. Relevant randomized controlled trials (RCTs) with an intervention duration of at least 16 weeks assessing seven GLP-1 receptor agonists and polyagonists (mazdutide, 6 or 4.5 mg; retatrutide, 12 or 8 mg; tir…	PMID 39305981

Regulatory status

Full feed →

31 Mar 2026FDAWarning letter

FDA warns peptide vendors selling retatrutide as a 'research' GLP-1

The FDA issued warning letters to research-peptide sellers — among them Prime Sciences and Gram Peptides — offering products labeled 'GLP-1-R', 'GLP1-S' and 'GLP1-T' that the agency identified as retatrutide, an investigational drug with no approved product that cannot lawfully be compounded. The letters cite unapproved-new-drug and misbranding violations for promoting the peptides for human use behind 'research use only' labeling, part of a broader 2026 enforcement push against GLP-1 and peptide sellers that also produced dozens of letters to telehealth firms marketing compounded GLP-1s.

Retatrutide

10 Dec 2024FDAWarning letter

FDA warning letter to SwissChems over semaglutide and retatrutide

The FDA warned SwissChems that its semaglutide and retatrutide products — sold as research chemicals but promoted for human weight and metabolic use — are unapproved new drugs and misbranded under the FD&C Act. It is one of a series of letters the agency has issued to vendors offering GLP-1 and research peptides directly to the public.

Semaglutide Retatrutide

Vendors listing Retatrutide

Ranked view →

The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.

Vendor	Score · Coverage	Certificates
Curo	93.877%	2	profile →
Polaris Peptides	93.877%	9	profile →
Next Gen Peptides	93.897%	2	profile →
Amino Club	90.495%	2	profile →
PeptidePlugs	89.790%	18	profile →
Hydro Research Peptides	88.289%	5	profile →
Prime Peptides	87.180%	1	profile →
American Peptides	83.6100%	5	profile →
Origin Labs	81.885%	3	profile →
Northline Labs	79.493%	1	profile →
ZC Labs	79.384%	5	profile →
Ascension Peptides	78.186%	2	profile →
Vertex Labs	70.170%	4	profile →
Disguised Alpha	69.150%	0	profile →
Evolve Peptides	65.567%	0	profile →
Mile High Compounds	65.494%	2	profile →

How to read this page

This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.